Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1/2 trial
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Background Aromatic l-amino acid decarboxylase (AADC) deficiency is an inherited disease that causes depletion of neurotransmitters and severe motor dysfunction in infants and children. We previously reported compassionate use of an adeno-associated virus (AAV) vector containing the human AADC gene (AAV2-hAADC) in four children with AADC deficiency (aged 4-6 years). In this study, we aimed to establish the efficacy and safety of this treatment.Methods We did an open-label, phase 1/2 trial at the National Taiwan University Hospital (Taipei, Taiwan). We included patients who had a definitive diagnosis and clinical symptoms of AADC deficiency (hypotonia, dystonia, and oculogyric crisis), who were older than 24 months or had skull bones suitable for stereotactic surgery, and who had an anti-AAV2 antibody titre lower than 1·0 optical density. All patients received bilateral intraputaminal injections of AAV2-hAADC (1·81 × 10 11 vg in total) through stereotactic brain surgery. Primary efficacy outcomes were an increase in the Peabody Developmental Motor Scales (second edition; PDMS-2) score of greater than 10 points and an increase in homovanillic acid (HVA) or 5-hydroxyindoleacetic acid (5-HIAA) concentrations in the cerebrospinal fluid 12 months after gene therapy. We assessed patients at baseline and at 3, 6, 9, and 12 months after gene therapy, and every 6 months thereafter for one further year; all patients who received the treatment were included in the analysis. We assessed for surgical complications (cerebrospinal fluid leakage and intracerebral haemorrhage) at days 3-7 after AAV2 gene therapy, and we assessed adverse events during the follow-up evaluations for 12 months. This study is registered with ClinicalTrials.gov, number NCT01395641.Findings Ten patients (median age 2·71 years, IQR 2·46-6·35) were enrolled from Oct 1, 2014, to Dec 2, 2015. All patients tolerated the surgeries and vector injections. One patient died from influenza B encephalitis during an endemic outbreak 10 months after treatment; therefore, 9 months of data were included in the analyses for this patient. All patients met the primary efficacy endpoint: 12 months after gene therapy, PDMS-2 scores were increased by a median of 62 points (IQR 39-93; p=0·005) and HVA concentrations by a median of 25 nmol/L (IQR 11-48; p=0·012); however, there was no significant change in 5-HIAA concentrations (median difference 0, IQR 0-5; p=0·20). In total, 101 adverse events were reported, with the most common being pyrexia (16 [16%] of 101 events) and orofacial dyskinesia (ten [10%]). 12 serious adverse events occurred in six patients, including one death (treatment-unrelated encephalitis due to influenza B infection), one life-threatening pyrexia, and ten events that led to hospital admission. Transient post-gene therapy dyskinesia occurred in all patients but was resolved with risperidone. Of 31 treatment-related adverse events, only one (patient 1) was severe in intensity, and none led to hospital admission or death.Interpretation Our findings suggest that intraputaminal injection of AAV2-hAADC is well tolerated and might improve motor development in children with AADC deficiency.Funding AADC Research Fund at National Taiwan University Hospital and the National Research Programme for Biopharmaceuticals.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“One subject died from an unrelated cause”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [60]
In the citing paper
“Reported AEs included pyrexia and transient orofacial dyskinesia that resolved with risperidone.60”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [60]
In the citing paper
“an additional ten children, ages 24 months and up, with confirmed AADC deficiency diagnoses were dosed with intraputaminal AAV2-hAADC.”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [60]
In the citing paper
“the remaining survivors demonstrated remarkable improvements in motor functioning (increase of 62 points on the Peabody Developmental Motor Scale)”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [60]
Citations
Cites
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
Nakai, H., Yant, S. R., Storm, T. A., Fuess, S., Meuse, L., & Kay, M. A. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.6969-6976.2001 · Cited by 478
A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson’s disease
Muramatsu, S.-I., Fujimoto, K.-I., Kato, S., Mizukami, H., Asari, S., Ikeguchi, K., Kawakami, T., Urabe, M., Kume, A., Sato, T., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.135 · Cited by 344
Self-citationLong-term follow-up after gene therapy for canavan disease
Leone, P., Shera, D., McPhee, S. W. J., Francis, J. S., Kolodny, E. H., Bilaniuk, L. T., Wang, D.-J., Assadi, M., Goldfarb, O., Goldman, H. W., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003454 · Cited by 307
Watakabe, A., Ohtsuka, M., Kinoshita, M., Takaji, M., Isa, K., Mizukami, H., Ozawa, K., Isa, T., & Yamamori, T. (2015) · Neuroscience Research · doi:10.1016/j.neures.2014.09.002 · Cited by 303
Long-Term Evaluation of a Phase 1 Study of AADC Gene Therapy for Parkinson's Disease
Mittermeyer, G., Christine, C. W., Rosenbluth, K. H., Baker, S. L., Starr, P., Larson, P., Kaplan, P. L., Forsayeth, J., Aminoff, M. J., & Bankiewicz, K. S. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.220 · Cited by 298
Tardieu, M., Zérah, M., Husson, B., de Bournonville, S., Deiva, K., Adamsbaum, C., Vincent, F., Hocquemiller, M., Broissand, C., Furlan, V., et al. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.238 · Cited by 261
Gene Therapy for Aromatic l -Amino Acid Decarboxylase Deficiency
Hwu, W.-L., Muramatsu, S.-I., Tseng, S.-H., Tzen, K.-Y., Lee, N.-C., Chien, Y.-H., Snyder, R. O., Byrne, B. J., Tai, C.-H., & Wu, R.-M. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003640 · Cited by 246
Self-citationWassenberg, T., Molero-Luis, M., Jeltsch, K., Hoffmann, G. F., Assmann, B., Blau, N., Garcia-Cazorla, A., Artuch, R., Pons, R., Pearson, T. S., et al. (2017) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-016-0522-z · Cited by 239
Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency
Brun, L., Ngu, L. H., Keng, W. T., Ch'ng, G. S., Choy, Y. S., Hwu, W. L., Lee, W. T., Willemsen, M. A. A. P., Verbeek, M. M., Wassenberg, T., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e620ae · Cited by 226
Self-citation
Cited by
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
Self-citationTherapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality
Hudry, E., & Vandenberghe, L. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.017 · Cited by 369
Various AAV Serotypes and Their Applications in Gene Therapy: An Overview
Issa, S. S., Shaimardanova, A. A., Solovyeva, V. V., & Rizvanov, A. A. (2023) · Cells · doi:10.3390/cells12050785 · Cited by 313
Metadata
- Authors
- Chien, Y.-H., Lee, N.-C., Tseng, S.-H., Tai, C.-H., Muramatsu, S.-I., Byrne, B. J., & Hwu, W.-L.
- Affiliations
- National Taiwan University (TW)
- Jichi Medical University (JP)
- University of Florida (US)
- Corresponding author
- Hwu, Wuh-Liang
- ORCID
- Venue
- The Lancet Child & Adolescent Health
- Publisher
- Elsevier BV
- Published
- 2017-12
- Volume
- 1
- Issue
- 4
- Pages
- 265-273
- ISSN
- 2352-4642 (ISSN-L)
- OpenAlex
- W2766287718
- Cited by
- 142
- References
- 26
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 20 · 2023: 20 · 2022: 17 · 2021: 22 · 2020: 24 · 2019: 12 · 2018: 3 · 2017: 1
- FWCI
- 7.27
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet Child & Adolescent Health (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Taiwan University Hospital
- Fujita Health University
- Food and Drug Administration
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- aromatic L-amino acid decarboxylase deficiency, adeno-associated virus vectors, homovanillic acid, 5-hydroxyindoleacetic acid, motor function, neurotransmitter depletion, motor impairment, adverse events, pediatric neurodegenerative disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1/2 trial. https://app.cochat.ai/papers/10.1016/s2352-4642(17)30125-6
- The paper
- Chien, Y.-H., Lee, N.-C., Tseng, S.-H., Tai, C.-H., Muramatsu, S.-I., Byrne, B. J., & Hwu, W.-L. (2017). Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1/2 trial. The Lancet Child & Adolescent Health. https://doi.org/10.1016/s2352-4642(17)30125-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.